pain management

When SPCH debuted on the Catalist Board, its intention was to become a “disruptive force” in the healthcare sector

SINGAPORE (Oct 13): DBS Group Research has derived a fair value estimate of 43 cents for iX Biopharma in its preliminary assessment of what it deems a high-risk stock, with a view that investors should expect 0-20% potential returns from the stock over th